Recommendations for adjuvant therapy for stage 2 colon cancer from the American Society of Clinical Oncology (ASCO)
ASCO recommends that adjuvant chemotherapy should be offered to patients with stage IIA colon cancer and high-risk features, and patients with stage IIB and IIC colon cancer.
High-risk features are: perineural or lymphovascular invasion, poorly differentiated tumor grade, undifferentiated tumor grade, intestinal obstruction, tumor perforation, ≥10 tumor buds, or <12 lymph nodes in surgical specimen. The number of risk factors present should be considered in the shared decision-making process, because the presence of more than one risk factor may increase risk of recurrence.
Patients with high-risk stage IIA, or stage IIB or stage IIC colon cancer should be offered therapy for 3 to 6 months, after an individualized discussion of the potential benefits and harms of the treatment and its duration.
Adjuvant chemotherapy should not be offered routinely to people with stage IIA colon cancer without high-risk features.
Colorectal cancer is the third most common cancer in the developed world, and the fourth leading cause of cancer deaths in the US.
Rare below 40 years of age.
Symptoms are not specific and occur frequently in benign colorectal conditions.
Surgical resection is the main curative treatment.
Combined multi-modality treatment (chemotherapy, radiation therapy, immunotherapy, resection of metastases) has greatly reduced local recurrence and increased survival in selected cases.
The majority of colorectal cancers are adenocarcinomas derived from epithelial cells. About 66% of new colorectal cancers arise in the colon (43% in the proximal colon and 23% in the distal colon) and 30% occur in the rectum. Less common types of malignant colorectal tumors are carcinoid tumors, gastrointestinal stromal cell tumors, and lymphomas. Increasing age is the greatest risk factor for sporadic colorectal adenocarcinoma, with 99% of cancers occurring in people ages 40 years or over.
History and exam
Key diagnostic factors
- increasing age
- rectal bleeding
- change in bowel habit
- rectal mass
- positive family history
- abdominal mass
Other diagnostic factors
- male sex
- abdominal pain
- weight loss and anorexia
- abdominal distension
- palpable lymph nodes
- increasing age
- family history
- adenomatous polyposis coli mutation
- Lynch syndrome (hereditary nonpolyposis colorectal cancer)
- MUTYH/MYH-associated polyposis
- hamartomatous polyposis syndromes
- inflammatory bowel disease
- limited physical activity
- lack of dietary fiber
1st investigations to order
- complete blood count
- liver biochemistry
- renal function
- CT colonography
- double-contrast barium enema
- CT scan of chest, abdomen, and pelvis
- genetic testing
Investigations to consider
- MRI pelvis rectal cancer protocol
- transrectal endoscopic ultrasound
- carcinoembryonic antigen
- PET scan
- advanced optical imaging techniques
rectal cancer, suitable for surgery
rectal cancer, not suitable for surgery
colon cancer, suitable for surgery
colon cancer, not suitable for surgery
David E. Stein, MD, FACS, FASCRS
Regional Chief of Surgery
DES declares that he has no competing interests.
David M. Lisle, MD
Associate Program Director
Department of Surgery
MedStar Franklin Square Medical Center
DML declares that he has no competing interests.
Pallavi P. Kumar, MD
Division Director, Medical Oncology
Sinai and Northwest Hospital
Alvin & Lois Lapidus Cancer Institute
PPK declares that she has no competing interests.
Kamila A. Nowak-Choi, MD
Department of Radiation Oncology
MedStar Franklin Square Medical Center
KANC declares that she has no competing interests.
Dr David E. Stein, Dr David M Lisle, Dr Pallavi P Kumarm, and Dr Kamila A Nowak-Choi would like to gratefully acknowledge Dr Juan L. Poggio, Dr Jascha Rubin, Dr Najjia Mahmoud, Dr Emily Carter Paulson, Dr Gary Atkin, Dr Anne Ballinger, Dr Mark O'Hara, Dr Mark Harrison, and Dr Robert Glynne-Jones, previous contributors to this topic.
JLP, JR, NM, ECP, MOH, GA, and AB declare that they have no competing interests. MH is the chair of the Mount Vernon Upper GI Tumour Site Specific Group and a member of the National Cancer Research Institute anal, rectal, and advanced colorectal groups. He has also received honoraria for speaking and has been supported to attend international meetings in gastrointestinal (GI) cancer from Roche. He has also received research funding from Pfizer for a trial in rectal cancer. RGJ is the chief medical adviser to the charity Bowel Cancer UK. He has received honoraria for lectures from Roche, Sanofi, and Pfizer. He has received funding for the EXTRA study, involving capecitabine and radiotherapy in anal cancer, published in the International Journal of Radiation Biology Physics. RGJ has also received funding and free cetuximab for an ongoing phase 1/2 study integrating cetuximab into chemoradiation in rectal cancer, and has an agreement from Roche to supply bevacizumab for 3 months to 60 patients in one randomised phase 2 study as neoadjuvant chemotherapy in rectal cancer (BACCHUS). He has also been supported by Roche to attend international meetings in GI cancer.
Susan Clark, BChir, MB
Consultant Colorectal Surgeon
St Mark's Hospital and Academic Institute
SC declares that she has no competing interests.
Steven Wexner, MD, FACS, FRCS, FRCS Ed, FASCRS, FAC
Chief of Staff
Department of Colorectal Surgery
SW declares that he has no competing interests.
- Irritable bowel syndrome
- Ulcerative colitis
- Crohn disease
- The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of colon cancer
- Treatment for brain metastases: ASCO-SNO-ASTRO guideline
Colon and rectal cancer: should I be screened?
Colon and rectal cancer: what is it?More Patient leaflets
- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer